Subgroup analysis of patients (pts) with HER2-low metastatic breast cancer (mBC) with brain metastases (BMs) at baseline from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC)

被引：8
|
作者：
Tsurutani, J. [1 ]
Jacot, W. [2 ]
Yamashita, T. [3 ]
Riaz, F. [4 ]
Yerushalmi, R. [5 ]
Im, S-A. [6 ]
Niikura, N. [7 ]
Halser-Strub, U. [8 ]
Cortes, J. [9 ,10 ]
Wennstig, A-K. [11 ]
Chae, Y. [12 ]
Wang, X. [13 ]
Li, W. [14 ]
Simon, H. [15 ]
Masci, G. [16 ]
Tamburini, E. [17 ]
Aguilar, C. Orbegoso [18 ]
Tecson, K. [19 ]
Yung, L. [20 ]
Modi, S. [21 ]
机构：
[1] Showa Univ Hosp, Adv Canc Translat Res Inst, Tokyo, Japan
[2] Inst Canc Montpellier, Med Oncol, Montpellier, France
[3] Kanagawa Canc Ctr, Breast Surg & Oncol, Yokohama, Kanagawa, Japan
[4] Stanford Sch Med, Med Oncol, Stanford, CA USA
[5] Tel Aviv Univ, Inst Oncol, Davidoff Ctr, Rabin Med Ctr, Petah Tiqwa, Israel
[6] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Dept Internal Med, Seoul, South Korea
[7] Tokai Univ, Breast Oncol, Sch Med, Isehara, Kanagawa, Japan
[8] Kantonsspital St Gallen, Breast Ctr, St Gallen, Switzerland
[9] Int Breast Canc Ctr, Oncol, Pangaea Oncol, Quironsalud Grp, Madrid, Spain
[10] Int Breast Canc Ctr, Oncol, Pangaea Oncol, Quironsalud Grp, Barcelona, Spain
[11] Sundsvall Hosp, Oncol, Sundsvall, Sweden
[12] Kyungpook Natl Univ, Med Oncol, Chilgok Hosp, Daegu, South Korea
[13] Zhejiang Canc Hosp, Med Oncol, Canc Res Inst, Hangzhou, Peoples R China
[14] First Hosp Jilin Univ, Tumor Ctr, Changchun, Jilin, Peoples R China
[15] CHU Brest, Oncol, Hop Morvan, Inst Cancerol & Hematol, Brest, France
[16] Humanitas Clin Res Hosp Rozzano, Med Oncol, Rozzano, MI, Italy
[17] Pia Fdn Cardinale G Panico Hosp, Oncol & Palliat Care, Tricase, Italy
[18] Daiichi Sankyo France SAS, Global Oncol R&D, Rueil Malmaison, France
[19] Daiichi Sankyo Inc, Evidence Generat, Basking Ridge, NJ USA
[20] Daiichi Sankyo Inc, Global Oncol R&D, Basking Ridge, NJ USA
[21] Mem Sloan Kettering Canc Ctr, Med, New York, NY USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.565
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
388P
引用
收藏
页码：S342 / S343
页数：2
相关论文
共 50 条
  • [31] Analysis of study drug-related interstitial lung disease (ILD) in patients (pts) with HER2+metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (T-DXd)
    Powell, C. A.
    Modi, S.
    Iwata, H.
    Takahashi, S.
    Nie, K.
    Qin, A.
    Singh, J.
    Taitt, C.
    Verma, S.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2021, 32 : S61 - S62
  • [32] Trastuzumab deruxtecan (T-DXd; DS-8201) in HER2-positive (HER2+) and HER2-low expressing (HER-LE) metastatic breast cancer (MBC) with brain metastases (BM) and/or leptomeningeal carcinomatosis (LMC): DEBBRAH
    Vaz Batista, M.
    Perez-Garcia, J. M.
    Llombart Cussac, A.
    Cortez, P.
    Ruiz Borrego, M.
    De la Haba, J.
    Cejalvo, J. M.
    Racca, F.
    Servitja, S.
    Blanch, S.
    Lema, L.
    Galan Garmaje, M.
    Fernandez-Abad, M.
    Fernandez, A.
    Iranzo, V.
    Gonzalez-Santiago, S.
    Gion, M.
    Nave, M.
    Cortes, J.
    Braga, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S509 - S510
  • [33] Multicenter Retrospective Cohort Study of the Sequential Use of the Antibody-Drug Conjugates (ADCs) Trastuzumab Deruxtecan (T-DXd) and Sacituzumab Govitecan (SG) in Patients With HER2-Low Metastatic Breast Cancer (MBC)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2024, 22 (01)
  • [34] Trastuzumab Deruxtecan vs Physician's Choice in Patients With HER2+ Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine: Primary Results of the Randomized, Phase 3 Study DESTINY-Breast02
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (02) : 7 - 7
  • [35] Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC)
    Huppert, Laura
    Mahtani, Reshma
    Fisch, Samantha
    Dempsey, Naomi
    Premji, Sarah
    Raimonde-Taylor, Angelina
    Jacob, Saya
    Quintal, Laura
    Chien, Jo
    Melisko, Michelle
    Sandoval-Leon, Ana
    Carcas, Lauren
    Ahluwalia, Manmeet
    Harpalani, Natasha
    Hoppenworth, Jenna
    Idossa, Dame
    Rao, Ruta
    Giridhar, Karthik
    Rugo, Hope
    CANCER RESEARCH, 2024, 84 (09)
  • [36] Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC)
    Laura A. Huppert
    Reshma Mahtani
    Samantha Fisch
    Naomi Dempsey
    Sarah Premji
    Angelina Raimonde
    Saya Jacob
    Laura Quintal
    Michelle Melisko
    Jo Chien
    Ana Sandoval
    Lauren Carcas
    Manmeet Ahluwalia
    Natasha Harpalani
    Jenna Hoppenworth
    Anne Blaes
    Kelly Blum
    Mi-Ok Kim
    Dame Idossa
    Ruta Rao
    Karthik V. Giridhar
    Hope S. Rugo
    npj Breast Cancer, 11 (1)
  • [37] Trastuzumab deruxtecan vs physician's choice in patients with HER2+unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: primary results of the randomized, phase 3 study DESTINY-Breast02
    Krop, Ian
    Park, Yeon H.
    Kim, Sung-Bae
    Borges, Giuliano
    Aksoy, Sercan
    Gregori, Joaquin Gavila
    Roylance, Rebecca
    Lim, Elgene
    Yerushalmi, Rinat
    Zagouri, Flora
    Duhoux, Francois P.
    Fehm, Tanja
    Takano, Toshimi
    Egorov, Anton
    Wu, Iris
    Cathcart, Jillian
    Chu, Changan
    Andre, Fabrice
    CANCER RESEARCH, 2023, 83 (05)
  • [38] Trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients (pts) with active brain metastases: Primary outcome analysis from the TUXEDO-1 trial
    Bartsch, R.
    Berghoff, A. S.
    Furtner, J.
    Marhold, M.
    Bergen, E. S.
    Roider-Schur, S.
    Starzer, A. M.
    Forstner, H.
    Rottenmanner, B.
    Dieckmann, K.
    Bago-Horvath, Z. A.
    Widhalm, G.
    Ilhan-Mutlu, A.
    Minichsdorfer, C.
    Fuereder, T.
    Singer, C. F.
    Weltermann, A.
    Puhr, R.
    Preusser, M.
    ANNALS OF ONCOLOGY, 2022, 33 : S198 - S198
  • [39] Trastuzumab deruxtecan (T-DXd) vs physician's choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06)
    Curigliano, Giuseppe
    Hu, Xichun
    Dent, Rebecca Alexandra
    Yonemori, Kan
    Barrios Sr, Carlos H.
    O'Shaughnessy, Joyce
    Wildiers, Hans
    Zhang, Qingyuan
    Im, Seock-Ah
    Saura, Cristina
    Biganzoli, Laura
    Sohn, Joohyuk
    Levy, Christelle
    Jacot, William
    Begbie, Natasha
    Ke, Jun
    Patel, Gargi Surendra
    Bardia, Aditya
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA1000 - LBA1000
  • [40] ERIBULIN MESYLATE (E7389) VS TREATMENT OF PHYSICIAN'S CHOICE (TPC) IN PATIENTS (PTS) WITH METASTATIC BREAST CANCER (MBC): SUBGROUP ANALYSES FROM THE EMBRACE STUDY
    Twelves, C.
    Akerele, C.
    Wanders, J.
    Cortes, J. A.
    ANNALS OF ONCOLOGY, 2010, 21 : 96 - 96
12345